Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Posts 33 Percent Rise in Q2 Revenues, Notes Strong Interest in New Mass Spec Systems

Premium

Bruker this week reported a 33 percent increase year over year in Q2 revenues with its Scientific Instruments division, which houses its mass spectrometry business, also growing 33 percent.

While CEO Frank Laukien noted during a call discussing the results that recent mass spec releases like the maXis 4G UHR-QTOF and the maXis Impact likely hadn't contributed to these revenues, he said "order uptake is strong" for the new instruments, and they are "getting very good traction, very good interest."

For the three months ended June 30, the company posted $401.2 million in revenues, up from $300.9 million a year ago, surpassing analysts' forecasts of $384.1 million. Its Scientific Instruments division totaled $377.9 million in revenues, compared to $284.9 million a year ago.

Like other mass spec vendors (PM 07/29/2011), Bruker saw some weakness in the academic and government-funded markets, a trend Laukien said the company expects to continue – particularly in the US – in the second half of the year.

Academic funding in Europe and Asia, however, "has been quite good," he noted.

Bruker's profit for the quarter slid 2 percent to $22.1 million, or $.13 per share, from $22.6 million, or $.14 a share, a year ago. On an adjusted basis, EPS was $.20, just short of the consensus Wall Street estimate of $.21.

The firm's R&D expenses increased to $44.3 million from $31.2 million, a 42 percent uptick. Its SG&A costs rose 52 percent to $97.5 million from $64 million a year ago.

Bruker ended the quarter with $173.1 million in cash, cash equivalents, and restricted cash.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.